PositiveReview/Other2016
A cost-effectiveness model for the use of a cannabis-derived oromucosal spray for the treatment of spasticity in multiple sclerosis.
Classification Results
AI Classification
PositiveFine-tuned Classification
PositiveAI Classification
PositiveFine-tuned Classification
PositiveUnraveling endocannabinoid signaling disruption in a preclinical model of neurodevelopmental disorders